Catalent has the broadest drug development toolkit, offering clients multiple technologies to enhance the bioavailability and solubility of drugs during formulation.
Micronisation is a proven, dependable and versatile method to achieve high quality particle size reduction to assist in API and formulation optimisation. Catalent Micron Technologies is a global leader in particle size reduction services, delivering high quality micronisation, milling, and analytical services. Its full range of capabilities includes:
• Development through to commercial scale
• Micronisation (jet mill)
• Mechanical milling (hammer mill, pin mill)
• Cryogenic milling
• Controlled handling of potent and cytotoxic compounds
• Comprehensive supporting analytical services
Spray drying can also assist in overcoming formulation and development challenges, and from its facility in San Diego, Catalent offers this service from early phase development through to clinical manufacturing scale. With over 75 years’ experience in spray drying and amorphous dispersion technology, the Pharmatek SD spray drying team can fully characterise an API and associated formulations throughout feasibility, development, and commercialisation, to provide a robust data package in support of regulatory filings.
The Pharmatek SD spray drying technology offered by Catalent is integrated into its extended OptiForm Solution Suite platform, which allows drug developers to gain an insight into accelerating programmes from late-stage discovery to phase I trials.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.